Drug Trial Radar · NCT05225857
A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women
Last checked: Nov 19, 2026Latest source record: Feb 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Jun 28, 2022
Primary completion
Jan 13, 2024
Study completion Jan 13, 2024
Sponsor
- Lead sponsor
- Angitia BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Angitia Australia Pty Ltd
- First posted
- Feb 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to assess the safety and tolerability of AGA2118 after single subcutaneous or intravenous administration in healthy men and postmenopausal women and to assess the safety and tolerability of AGA2118 after multiple subcutaneous administrations in men and postmenopausal women.
Conditions
- Osteoporosis
Interventions
AGA2118Drug
Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV. Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC.
PlaceboDrug
Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV. Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAE) in Part 1 (SAD).Time frame: Up to 85 days
- Number of participants with clinically significant changes in total calcium (albumin-adjusted) in Part 1 (SAD).Time frame: Up to 85 days
- Number of participants with clinically significant changes in blood pressure in Part 1 (SAD).Time frame: Up to 85 days
- Number of participants with clinically significant changes in heart rate in Part 1 (SAD).Time frame: Up to 85 days
- Number of participants with clinically significant changes in QTcF in Part 1 (SAD).Time frame: Up to 85 days
- Number of participants with treatment-emergent adverse events (TEAE) in Part 2 (MAD).Time frame: Up to 169 days
- Number of participants with clinically significant changes in total calcium (albumin-adjusted) in Part 2 (MAD).Time frame: Up to 169 days
- Number of participants with clinically significant changes in blood pressure in Part 2 (MAD).Time frame: Up to 169 days
- Number of participants with clinically significant changes in heart rate in Part 2 (MAD).Time frame: Up to day 169
- Number of participants with clinically significant changes in QTcF in Part 2 (MAD).Time frame: Up to day 169
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Ltd
Brisbane, Queensland, Australia
Nucleus Network Pty Ltd.
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.